TD Private Client Wealth LLC Lowers Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

TD Private Client Wealth LLC decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 951 shares of the medical research company’s stock after selling 80 shares during the quarter. TD Private Client Wealth LLC’s holdings in IQVIA were worth $187,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Lee Danner & Bass Inc. purchased a new position in shares of IQVIA during the 4th quarter worth about $44,000. Whittier Trust Co. of Nevada Inc. raised its stake in IQVIA by 4.9% during the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 51,614 shares of the medical research company’s stock worth $10,142,000 after purchasing an additional 2,432 shares during the period. Douglass Winthrop Advisors LLC grew its stake in shares of IQVIA by 7.6% during the 4th quarter. Douglass Winthrop Advisors LLC now owns 471,533 shares of the medical research company’s stock valued at $92,661,000 after buying an additional 33,455 shares during the period. Holderness Investments Co. raised its position in shares of IQVIA by 22.9% in the 4th quarter. Holderness Investments Co. now owns 2,391 shares of the medical research company’s stock worth $470,000 after buying an additional 445 shares during the period. Finally, Northwest & Ethical Investments L.P. boosted its holdings in IQVIA by 6.9% in the fourth quarter. Northwest & Ethical Investments L.P. now owns 14,319 shares of the medical research company’s stock valued at $2,814,000 after acquiring an additional 919 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the topic of several recent research reports. Morgan Stanley lifted their target price on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th. Barclays dropped their price target on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Finally, UBS Group dropped their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Stock Down 2.7 %

IQV stock opened at $181.07 on Wednesday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm’s 50-day simple moving average is $194.24 and its 200 day simple moving average is $207.29. The stock has a market cap of $31.93 billion, a PE ratio of 24.14, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $253.84.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.